NASDAQ:ANCNANCHIANO THERAP/S Stock Price, Forecast & News

ANCHIANO THERAP/S's stock was trading at $0.8191 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ANCN stock has increased by 89.2% and is now trading at $1.55. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANCHIANO THERAP/S in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ANCHIANO THERAP/S.

ANCHIANO THERAP/S is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for ANCHIANO THERAP/S.

ANCHIANO THERAP/S (NASDAQ:ANCN) announced its quarterly earnings data on Thursday, May, 7th. The company reported ($0.41) EPS for the quarter, beating the Zacks' consensus estimate of ($0.55) by $0.14. View ANCHIANO THERAP/S's earnings history.

3 analysts have issued 1 year target prices for ANCHIANO THERAP/S's stock. Their forecasts range from $16.00 to $16.00. On average, they anticipate ANCHIANO THERAP/S's stock price to reach $16.00 in the next year. This suggests a possible upside of 932.3% from the stock's current price. View analysts' price targets for ANCHIANO THERAP/S.

News stories about ANCN stock have been trending negative on Saturday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ANCHIANO THERAP/S earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the company's share price in the near term. View the latest news about ANCHIANO THERAP/S.

Some companies that are related to ANCHIANO THERAP/S include IMMUTEP LTD/S (IMMP), Adamis Pharmaceuticals (ADMP), Novan (NOVN), RegeneRx Biopharmaceuticals (RGRX), American Bio Medica (ABMC), Q BioMed (QBIO), Guardion Health Sciences (GHSI), Akari Therapeutics (AKTX), Sernova (SEOVF), Hoth Therapeutics (HOTH), Neos Therapeutics (NEOS), Advaxis (ADXS), CNS Pharmaceuticals (CNSP), SONNET BioTherapeutics (SONN) and AgeX Therapeutics (AGE). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ANCHIANO THERAP/S investors own include AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Amplify Energy (AMPY), Amplify Energy (AMPY), Algonquin Power & Utilities (AQN), BCE (BCE), Franklin Resources (BEN), Bank of Nova Scotia (BNS), British American Tobacco (BTI) and Carnival (CCL).

(ANCN) raised $35 million in an initial public offering on Tuesday, February 12th 2019. The company issued 2,400,000 shares at $14.55 per share. Oppenheimer served as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

ANCHIANO THERAP/S trades on the NASDAQ under the ticker symbol "ANCN."

Shares of ANCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ANCN stock can currently be purchased for approximately $1.55.

ANCHIANO THERAP/S has a market capitalization of $11.50 million. The company earns $-27,120,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. ANCHIANO THERAP/S employs 19 workers across the globe.

The official website for ANCHIANO THERAP/S is www.anchiano.com.

ANCHIANO THERAP/S's mailing address is ONE KENDALL SQUARE BUILDING 400 SUITE 14-105, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-4622 or via email at [email protected]